Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue

Journal of Clinical Psychiatry

Volumn 65, Issue 3, 2004, Pages 414-420

  Ninan, Philip T ^a   Hassman, Howard A ^b   Glass, Steven J ^b   McManus, Frank C ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CNS Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT; FLUOXETINE; MODAFINIL; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG COMBINATION; FATIGUE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; PILOT STUDY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; SOMNOLENCE;

ADOLESCENT; ADULT; AGED; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISORDERS OF EXCESSIVE SOMNOLENCE; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 2342558582     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0318     Document Type: Article

References (34)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Maurice-Tison S, Verdoux H, Gay B, et al. How to improve recognition and diagnosis of depressive syndromes using international diagnostic criteria. Br J Gen Pract 1998;48:1245-1246 (Pubitemid 28221102)
3. Tylee A, Gastpar M, Lepine JP, et al. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 1999;14:139-151 (Pubitemid 29348767)
4. Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994;42:281-290 (Pubitemid 24796341)
5. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 1999;60:221-225 (Pubitemid 29193918)
6. Beasley CM Jr, Koke SC, Nilsson ME, et al. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther 2000;22:1319-1330
7. Zajecka JM. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry 2000;61(suppl 2):20-25 (Pubitemid 30131899)
8. Prozac (fluoxetine). Physicians' Desk Reference, 57th ed. Montvale, NJ: Medical Economics; 2003:1232-1237
9. Paxil (paroxetine). Physicians' Desk Reference, 57th ed. Montvale, NJ: Medical Economics; 2003:1603-1610
10. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108 (Pubitemid 28551779)
11. Tranter R, O'Donovan C, Chandarana P, et al. Prevalence and outcome of partial remission in depression. J Psychiatry Neurosci 2002;27:241-247 (Pubitemid 34988904)
12. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000;157:1423-1428 (Pubitemid 30677134)
13. Chouinard G, Saxena B, Belanger MC, et al. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 1999;54:39-48 (Pubitemid 29287671)
14. Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 2001;62(suppl 4):17-23 (Pubitemid 32184337)
15. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628
16. Stahl S. Psychopharmacology of wakefulness: pathways and neurotransmitters [BRAINSTORMS]. J Clin Psychiatry 2002;63:551-552 (Pubitemid 34787317)
17. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
18. Beusterien KM, Rogers AE, Walsleben JA, et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999;22:757-765 (Pubitemid 29445343)
19. Cassel W, Heitmann J, Kemeny C. Short term effects of modafinil on sleepiness in patients with sleep disordered breathing [abstract]. J Sleep Res 1998;7(suppl 2):83
20. Pack AI, Black JE, Schwartz JRL, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001;164:1675-1681 (Pubitemid 33124158)
21. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61: 378-381 (Pubitemid 30345941)
22. DeBattista C, Doghramji K, Menza M, et al, for the Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:1057-1064 (Pubitemid 37158251)
23. Markovitz P, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy. J Clin Psychopharmacol 2003;23:1-3 (Pubitemid 36368801)
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. Mini-International Neuropsychiatric Interview (MINI). Tampa, Fla: University of South Florida, Institute for Research in Psychiatry, and Paris, France: INSERM-Hôpital de la Salpêtrière; 1994
25. Krupp LB, LaRocca NG, Muir-Nash J, et al. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123 (Pubitemid 19246303)
26. Williams J. A Structured Interview Guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988;45:742-747 (Pubitemid 18189914)
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
28. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540-545
29. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): 2, psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247-263
30. Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am 2002;25:685-698 (Pubitemid 35351201)
31. De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993;87:141-145 (Pubitemid 23062205)
32. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42:123-137 (Pubitemid 36188553)
33. Ninan PT, Feigon SA, Knight B. Neurobiology and mechanisms of antidepressant treatment response in anxiety. Psychopharmacol Bull 2002;36(suppl 3):67-78
34. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809; comment 757 (Pubitemid 36962615)